Links to Homepage of ENHERTU (fam-trastuzumab deruxtecan-nxki) Patient Website Links to Homepage of ENHERTU (fam-trastuzumab deruxtecan-nxki) Patient Website

ENHERTU is FDA-approved for the treatment of several types of cancer

Don’t know your HER2 status? Talk to your healthcare provider.
Not actual patients.
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
*A solid tumor is a mass of cancer cells that grows in organs, muscles, or bones.

What is ENHERTU?

ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have:

  • Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
    • For metastatic disease, or
    • Have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
  • HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy:
    • For metastatic disease, or
    • Your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
  • Non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
    • ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.
  • Stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
  • Solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and who have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
    • ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.
  • It is not known if ENHERTU is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.